RT

Rondo Therapeutics at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

Rondo Therapeutics takes part in 3 sessions at Antibody Engineering 2026 in San Diego. Its program centers on T cell engagers and on antibodies that bind more than two targets. Its research pairs one engager that switches T cells on with another that gives them a second, boosting signal, to treat ovarian cancer.

OrganizationAntibody Engineering 2026 Attendance
RT
Rondo Therapeutics
Hayward, CA
Biotech
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors.
Talk
Tue Dec 15
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 1: Engineering and Biological Principles for Cell Engagers · with National Cancer Institute
Talk
Tue Dec 15
2:30pm–3:00pm
Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer
Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs.
Talk
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Regeneron

Explore the full Antibody Engineering 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full Antibody Engineering 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Rondo Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction